Clinical Trial Update: An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating immunogenicity and pharmacokinetics of Daclizumab High Yield Process Prefilled Syringe in Relapsing-Remitting Multiple Scler…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Daclizumab HYP (daclizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2017-03-14